• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

10-year Australian Trends in Periprocedural Complications after PCI
We examined the incidence and predictors of bleeding, acute kidney injury (AKI) and stroke following PCI, and their impact on 30-day outcomes.
Source: Heart, Lung and Circulation - July 26, 2016 Category: Cardiology Authors: S. Biswas, N. Andrianopoulos, A. Brennan, A. Ajani, J. Lefkovits, R. Warren, S. Duffy, D. Clark, G. New, C. Hiew, C. Reid, D. Eccleston Tags: 379 Source Type: research

Left Atrial Appendage Closure in Patients with Contra-Indications to Anticoagulants
This study sought to evaluate the utility of LAA device occlusion alone without OAC in patients at high risk of stroke but at serious risk of bleeding.
Source: Heart, Lung and Circulation - July 26, 2016 Category: Cardiology Authors: S. Kumar, V. Paul, R. Mahajan, J. Marangou, P. Waddy, D. Lau, H. Haqqani, P. Sanders Tags: 351 Source Type: research

Dual Versus Single Antiplatelet Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis
Although dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is a widely accepted strategy in patients undergoing transcatheter aortic valve replacement (TAVR), this approach is not evidence based. We therefore sought to systematically review the current evidence for this practice in terms of 30-day outcome looking at stroke, MI, bleeding, and death.
Source: Heart, Lung and Circulation - September 18, 2014 Category: Cardiology Authors: Madan Raj Aryal, Paras Karmacharya, Anil Pandit, Fayaz Hakim, Ranjan Pathak, Naba Raj Mainali, Anene Ukaigwe, Maryam Mahmood, Madan Badal, F. David Fortuin Tags: Original Article Source Type: research

Cardiac Surgery in Indigenous Australians: Early Onset Cardiac Disease with follow-up Challenges
Conclusions: The mean age of 52 years at which Indigenous patients have cardiac surgery is significantly low compared to non-Indigenous patients. Indigenous patients have multiple risk factors for cardiac disease and with a large number requiring emergency surgery. Although surgical outcome in the short term is favourable, a large number of patients are lost to follow-up. The use of mechanical valve and warfarin should be individualised. Strategic post-operative follow-up mechanisms are needed to address these issues.
Source: Heart, Lung and Circulation - February 24, 2014 Category: Cardiology Authors: M.P. Matebele, S. Rohde, A. Clarke, J.F. Fraser Tags: Original Articles Source Type: research

Percutaneous Transcatheter Left Atrial Appendage Closure Devices: Role in the Long-Term Management of Atrial Fibrillation
Conclusions: Percutaneous left atrial appendage occlusion is an exciting and novel therapy of stroke prevention in atrial fibrillation. Whilst further trials and long-term data are required prior to widespread implementation of this procedure, trials so far have highlighted the clinical efficacy of the procedure.
Source: Heart, Lung and Circulation - February 13, 2014 Category: Cardiology Authors: Chieh Howe (Gary) Gan, Aditya Bhat, Lloyd Davis, A. Robert Denniss Tags: Reviews Source Type: research

Transapical Aortic Valve Implantation—An Australian Experience
Conclusion: Good short-term outcomes and low or zero mortality are achievable with transapical TAVI at an Australian institution.
Source: Heart, Lung and Circulation - December 6, 2013 Category: Cardiology Authors: Michael Seco, Gonzalo Martinez, Paul G. Bannon, Bruce L. Cartwright, Mark Adams, Martin Ng, Michael K. Wilson, Michael P. Vallely Tags: Original Articles Source Type: research

Does Local Data Support RE-LY?—A One Year Case Series Looking at Major Bleeds on Vitamin K Antagonists Prescribed for Non-valvular AF
Introduction: The RE-LY trial showed that Dabigatran was non-inferior in stroke or systemic embolism prevention to Warfarin . Life threatening bleeding was less for the 110mg dose and similar for the 150mg dose to Warfarin .
Source: Heart, Lung and Circulation - June 24, 2013 Category: Cardiology Authors: V. Mathavan, C. Nunn Tags: Abstracts Source Type: research

Bleeding Events Associated with Novel Anticoagulants: A Case Series
Until lately warfarin was the only valuable oral anticoagulant in stroke reduction in high risk cases with non valvular atrial fibrillation (NVAF). Although with warfarin the rate of stroke reduced notably, the major concern is the risk of serious bleeding and difficulty of establishing and maintaining the international normalised ratio (INR) within the therapeutic range. With the development of the novel anticoagulants we now have for the first time since the innovation of Warfarin feasible alternatives to it to decrease stroke rates in high risk patients with NVAF. To diminish adverse bleeding events with the novel antic...
Source: Heart, Lung and Circulation - May 30, 2013 Category: Cardiology Authors: Sam Mirzaee, Tara Thi Thien Tran, John Amerena Tags: Clinical Spotlights Source Type: research

Dabigatran for Anticoagulation in Atrial Fibrillation – Early Clinical Experience in a Hospital Population and Comparison to Trial Data
Conclusion: In this population our study demonstrates a discontinuation rate of 10% due to side effects of dabigatran, similar to the rate reported in RE-LY. The majority of patients are satisfied with their treatment and preferred dabigatran to warfarin, mainly due to the reduced requirement for blood testing.
Source: Heart, Lung and Circulation - October 10, 2012 Category: Cardiology Authors: Jonathan Michel, David Mundell, Tau Boga, Alexander Sasse Tags: Original Articles Source Type: research

Pages: 1  2